Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

$24.99

Return on Assets (ROA)
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Eli Lilly & Co., ROA, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in thousands

The annual financial data reveals several notable trends in profitability, asset growth, and efficiency metrics over the assessed period.

Net Income
The net income demonstrates considerable variability over the years. Initially, it increased steadily from approximately $1.98 billion in 2005 to $2.95 billion in 2007. A significant negative dip occurred in 2008 with a loss of around $2.07 billion, followed by a strong recovery peaking at $8.32 billion in 2019. Subsequent years saw fluctuations with notable declines in 2014 and 2017, including another negative figure in 2017 at about -$204 million. An important surge is observed in 2024 with net income reaching $10.59 billion, the highest in the timeframe. Overall, net income exhibits periods of volatility but demonstrates strong growth potential and resilience.
Total Assets
Total assets grew overall, starting from approximately $24.58 billion in 2005 and showing a general upward trend, reaching $78.71 billion by 2024. Despite some fluctuations, such as a slight decrease between 2013 and 2015 and a temporary dip in 2019, the trend indicates substantial expansion in asset base over the period. This growth reflects ongoing investments and possible strategic acquisitions or capital expenditures.
Return on Assets (ROA)
ROA indicates profitability relative to asset size and exhibits notable fluctuations. It started at 8.05% in 2005 and peaked at 16.35% in 2010. A sharp negative return of -7.09% was recorded in 2008, corresponding with the net loss in that year, highlighting operational challenges. After recovery, ROA fluctuated mostly between 6% and 13%, with a dip to -0.45% in 2017, signaling another year of profitability pressure. The highest observed ROA was 21.17% in 2019, reflecting an exceptional efficiency in leveraging assets to generate earnings. The 2024 ROA of 13.45% shows a positive return despite increased asset base and heightened net income.

In summary, the data indicates a company with strong asset growth and varying profitability, including periods of losses and rebounds. The fluctuations in net income and ROA align, reflecting sensitivity to market or operational conditions. The recent years display significant improvement in both net income and ROA, suggesting enhanced operational efficiency and financial performance going forward.


Comparison to Competitors

Eli Lilly & Co., ROA, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Eli Lilly & Co., ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)